Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-05-14
2000-05-09
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514259, 544278, 544284, 544287, 544290, A61K 31505, C07D23972, C07D49502, C07D40104, C07D40300
Patent
active
060604794
ABSTRACT:
The present invention relates to novel quinazolin-4-one derivatives of the formula I, as defined in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
REFERENCES:
patent: 4183931 (1980-01-01), Wolfe et al.
Watkins, J.C., and Evans, R.H., Excitatory Amino Acid Transmitters, Annu. Rev. Pharmacol. Toxicol. 21, pp. 165-204 (1981).
Monaghan, Daniel T., et al., The Excitatory Amino Acid Receptors: Their Classes, Pharmacology, and Distinct Properties in the Function of the Central Nervous System, Annu. Rev. Pharmacol. Toxicol. 29 pp. 365-402 (1989).
Watkins, Jeff C., et al., Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists, TIPS-(vol. 11) pp. 25-33 Jan. 1990.
Schoepp, Darryle, et al., Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors, TIPS-(vol. 11) pp. 508-515 Dec. 1990.
McDonald, John W. and Johnston, Micheal V., Physiological and pathophysiological roles of excitatory amino acids during central nervous system development, Brain Res. Reviews 15, pp. 41-70 (1990).
Sheardown, Malcom J., et al., 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline: A Neuroprotectant for Cerebral Ischemia, Science Reports, vol. 247, pp. 571-574 Feb. 2, 1990.
Buchan, Alastair M., et al., Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia, NeuroReport 2, No. 8, pp. 473-476 (1991).
Le Peillet, Elaine, et al., The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat, Brain Res. 571, pp. 115-120 (1992).
Parks T.N., et al., Modulation of N-methyl-D-aspartate receptor-mediated increases in cytosolic calcium in cultured rat cerebellar granule cells, Brain Res. 552, pp. 13-22 (1991).
Wolfe, James F., et al., Synthesis and Anticonvulsant Activity of Some New 2-Substituted 3-Aryl-4 (3H)-quinazolinones, J. Med. Chem, 33, pp. 161-166, (1990).
Wolfe, James F., et al., Synthesis and Anticonvulsant Activity of Some New 3, 6-Disubstituted-2-[2-oxo-2-(4-pyridyl)ethyl]-4(3H)-pyrimidinones, Journal of Pharmaceutical Sciences, vol. 80, No.7, pp. 705-706 Jul. 1991.
Beal, M. Flint, Aging, Energy, and Oxidative Stress in Neurodegenerative Diseases, Annals of Neurology, vol. 38, No. 3, pp. 357-366, Sep. 1995.
Chenard Bertrand L.
Welch Willard M.
Coleman Brenda
Ginsburg Paul H.
Pfizer Inc
Raymond Richard L.
Richardson Peter C.
LandOfFree
Quinazoline-4-one AMPA antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline-4-one AMPA antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline-4-one AMPA antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1065385